Clinical TrialJun 3, 2026, 06:54 AM
Kura Oncology darlifarnib + adagrasib shows 67% ORR in pancreatic cancer
AI Summary
Kura Oncology presented new clinical and translational data at ASCO 2026, supporting darlifarnib as a potential foundational combination platform for KRAS-mutant cancers. Preliminary Phase 1a data from darlifarnib plus adagrasib demonstrated confirmed objective response rates of 67% in pancreatic cancer, 50% in non-small cell lung cancer, and 29% in KRAS inhibitor-naïve colorectal cancer. The company plans a new platform study to accelerate evaluation of darlifarnib across multiple targeted therapies, with the first combination (darlifarnib + daraxonrasib) expected to enter Phase 1a in early 2027.
Key Highlights
- Darlifarnib + adagrasib showed 67% objective response rate (ORR) in pancreatic cancer.
- Darlifarnib + adagrasib showed 50% ORR in non-small cell lung cancer.
- Darlifarnib + adagrasib showed 29% ORR in KRAS inhibitor-naïve colorectal cancer.
- Tumor shrinkage observed in 77% of overall patients and 94% of KRAS inhibitor-naïve patients.
- New platform study designed to accelerate darlifarnib evaluation across multiple combinations.
- First platform combination, darlifarnib + daraxonrasib, to enter Phase 1a in early 2027.
- Preclinical data supports broad applicability across evolving RAS inhibitor landscape.
Price Impact
More from KURA